Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Radiotherapy for Oligoresidual NSCLC
NCT07014202Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival. Started Jun 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07014202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014202.